Dosimetric and NTCP advantages of robust proton therapy over robust VMAT for Stage III NSCLC in the immunotherapy era.
Dionisi F, Landoni V, Widesott L, Nardangeli A, Fracchiolla F, Siniscalchi B, Soriani A, Turkaj A, Righetto R, Amelio D, Farace P, Goanta L, Trianni A, Lorentini S, Cianchetti M, Sanguineti G.
Dionisi F, et al. Among authors: farace p.
Phys Med. 2024 Jul;123:103410. doi: 10.1016/j.ejmp.2024.103410. Epub 2024 Jun 14.
Phys Med. 2024.
PMID: 38878630